Karyopharm Therapeutics Inc (NASDAQ:KPTI) Insider Sharon Shacham Sells 20,000 Shares of Stock
Karyopharm Therapeutics Inc (NASDAQ:KPTI) insider Sharon Shacham sold 20,000 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $12.00, for a total value of $240,000.00.
KPTI stock traded down $0.40 during midday trading on Thursday, reaching $11.31. 22,953 shares of the company traded hands, compared to its average volume of 1,490,197. Karyopharm Therapeutics Inc has a 52-week low of $3.92 and a 52-week high of $19.19. The company has a debt-to-equity ratio of 1.46, a quick ratio of 6.93 and a current ratio of 6.93. The business has a 50 day moving average of $9.20 and a 200-day moving average of $6.66. The firm has a market capitalization of $733.76 million, a price-to-earnings ratio of -3.59 and a beta of 2.41.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.26. Karyopharm Therapeutics had a negative return on equity of 154.75% and a negative net margin of 2,138.80%. The business had revenue of $9.49 million for the quarter. Research analysts anticipate that Karyopharm Therapeutics Inc will post -3.64 earnings per share for the current year.
A number of equities research analysts recently commented on KPTI shares. Wedbush boosted their target price on Karyopharm Therapeutics from $11.00 to $15.00 and gave the stock an “outperform” rating in a research report on Tuesday. ValuEngine upgraded Karyopharm Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 5th. BidaskClub upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, September 13th. HC Wainwright reiterated a “buy” rating and issued a $32.00 target price (up from $29.00) on shares of Karyopharm Therapeutics in a research report on Friday, July 5th. Finally, JPMorgan Chase & Co. upgraded Karyopharm Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $8.00 to $16.00 in a research report on Tuesday, July 23rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Karyopharm Therapeutics has an average rating of “Buy” and an average price target of $17.89.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for
the treatment of cancer and other major diseases. Karyopharm’s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.